1.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phas...
by Moreno, Carol
The lancet oncology, 2019, Vol.20 (1), p.43-56
2.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4,...
by Fleischmann, Roy, Prof
The Lancet (British edition), 2017, Vol.390 (10093), p.457-468
3.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
by Abou-Alfa, Ghassan K
The lancet oncology, 2020, Vol.21 (5), p.671-684
4.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
by Jones, Jeffrey A
The lancet oncology, 2018, Vol.19 (1), p.65-75
5.
Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
by Kim, Dong-Wan, MD
The lancet oncology, 2016, Vol.17 (4), p.452-463
6.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomise...
by Burmester, Gerd R, Prof
The Lancet (British edition), 2013, Vol.381 (9865), p.451-460
7.
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
by Laetsch, Theodore W
The lancet oncology, 2018, Vol.19 (5), p.705-714
8.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymp...
by Chanan-Khan, Asher, Prof
The lancet oncology, 2016, Vol.17 (2), p.200-211
9.
Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining
by Maruyama, Takeshi
Nature biotechnology, 2015, Vol.33 (5), p.538-542
10.
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
by Cocco, Emiliano
Nature medicine, 2019, Vol.25 (9), p.1422-1427
11.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
12.
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
by Yee, Andrew J, MD
The lancet oncology, 2016, Vol.17 (11), p.1569-1578
13.
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
by Curtis, Jeffrey R Jeffrey R
Annals of the rheumatic diseases, 2015, Vol.75 (5), p.831-841
14.
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
by Grasso, C.S
Nature medicine, 2015, Vol.21 (6), p.555-559
15.
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up...
by Kantarjian, Hagop M, Prof
The lancet oncology, 2011, Vol.12 (9), p.841-851
16.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
by Burger, Jan A, Dr
The lancet oncology, 2014, Vol.15 (10), p.1090-1099
17.
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
by Hovingh, G Kees, Dr
The Lancet (British edition), 2015, Vol.386 (9992), p.452-460
18.
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
by Martin-Broto, Javier
The lancet oncology, 2019, Vol.20 (1), p.134-144
19.
The molecular targets of approved treatments for pulmonary arterial hypertension
by Humbert, Marc
Thorax, 2016, Vol.71 (1), p.73-83
20.
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
by Dimopoulos, Meletios A, Dr Prof
The lancet oncology, 2016, Vol.18 (2), p.241-250
